Several studies have dissected the potential anti-MM activity exerted by epigenetic modifier-targeting agents, such as inhibitors of DNMTs, HDACs, EZH2; and confirmed their anti-neoplastic effect in pre-clinical models of MM, as shown both in vitro an in vivo. Here, EZH2 is linked to Miyoshi myopathy.